Annual report pursuant to Section 13 and 15(d)

Organization and Description of Business (Narrative) (Details)

v3.22.1
Organization and Description of Business (Narrative) (Details)
$ in Millions
 12 Months Ended
Oct. 06, 2021
USD ($)
Dec. 31, 2021
company
Number of partner companies that are publicly traded | company   4
Number of partner companies that have consummated strategic partnerships with industry leaders | company   3
Caelum [Member] | AstraZeneca [Member]    
Deconsolidation of consolidated partner company, percentage deconsolidated 100.00%  
Deconsolidation of consolidated partner company, upfront payment | $ $ 150  
Caelum [Member] | AstraZeneca [Member] | Maximum [Member]    
Deconsolidation of consolidated partner company, contingent payment | $ $ 350